There are new regulations on the amount of centralized procurement, and the non-selected varieties have a new chance

The news of centralized procurement has become increasingly difficult to stimulate the industry's attention, but the new policy launched by Henan on April 15 may bring changes to the pharmaceutical industry

Henan will start the second and fourth batches of national centralized procurement renewal contracts, and fill in the report with the renewal contracts of the first batch of selected varieties in the centralized procurement part of the province

All medical institutions should refer to the actual use of the previous procurement cycle

Moreover, Henan stipulates that, in principle, if the actual increase or decrease in usage exceeds 20%, it is necessary to explain the situation ; for medical institutions that deliberately under-report or fail to report, medical insurance departments at all levels must conduct interviews

In principle, if the actual usage increases or decreases by more than 20%, it is necessary to explain the situation

Such minor amendments to the rules will affect the fate of a large number of unselected varieties, leaving a silver lining

Such minor amendments to the rules will affect the fate of a large number of unselected varieties, leaving a silver lining

Harvesting more or less is not good for companies

In the previous centralized procurement conducted nationwide or in various provinces and cities, the procurement volume reported by hospitals was generally much lower than the actual consumption volume

It is not new that the actual use of medical institutions exceeds 200% or even 400% of the predicted purchase volume due to too few reports

Too few reports, resulting in the actual use of medical institutions exceeding 200% or even 400% of the predicted purchases

At the end of June 2021, the Yunnan Provincial Drug Collection Platform showed that acarbose, amoxicillin granules, metformin hydrochloride sustained-release tablets and other varieties increased the declaration work of national drug supplement supply enterprises

The actual supply in the first year is about 4 times the agreed amount, and the mining quota is exceeded

Large sales volume is not necessarily a good thing for enterprises

There are great uncertainties in the market, making it difficult for companies to judge

due to insufficient capacity

This time, Henan Province took the lead in restricting the amount of reports from medical institutions, requiring the increase or decrease to be guaranteed within 20%.

"Scientifically agree on the market purchase volume of the winning products"

It is generally believed in the industry that restricting the number of declarations by medical institutions will not only fully guarantee the production of the winning bidders, but also ensure that the non-bidding bidders will seize the remaining part of the market for centralized procurement and provide consumers with more treatment options

It can also ensure that non-bidding companies can seize the remaining part of the market for centralized procurement.

Due to inaccurate reports and a large increase in demand, the centralized procurement varieties actually occupy the absolute market.

Therefore, the slight adjustment in Henan's reporting volume policy this time can ensure the production plan of pharmaceutical companies, and at the same time give other companies a chance to survive

A large number of unselected companies can adjust their sales strategies reasonably, and on the basis of retaining part of the hospital market, calmly turn to private hospitals, retail pharmacies or pharmaceutical e-commerce channels to hedge against the impact of market shrinkage

However, on April 18, Henan announced in one breath the specific usage of all medical institutions in
Henan Province in the 14-province Drug Alliance, Jiangxi Drug Alliance, Hubei Traditional Chinese Medicine Alliance, and the sixth batch of national centralized procurement .

The specific usage of all medical institutions in Henan Province

Taking the data of the sixth batch of Guocai as an example, Henan reported a total of 578,800 human insulin injections, 543,700 insulin aspart injections, and more than 543,700 insulin aspart injections.
104,200
.

This may mean that in the future, when these centralized procurement contracts are renewed, Henan may promote the new rules for reporting volumes
.

Determining the amount of purchases is helpful for enterprises to adjust production and sales

Determining the amount of purchases is helpful for enterprises to adjust production and sales

Henan is not "the first to eat crabs".
Before that, some provinces have begun to restrict the number of collected varieties to be reported
.

In March 2021, the Liaoning Provincial Medical Insurance Bureau issued a notice stating that the second batch of national drug centralized procurement and renewal contracts, medical institutions that have filled in the varieties, can increase by 10% according to the reported volume in 2020, even if the patients have strong requirements, the maximum increase is 200.
%
.

The medical institutions that have filled in the varieties can increase by 10% according to the reported volume in 2020, and even if the patients have strong requirements, the increase can be increased by up to 200%

Liaoning has consciously limited and regulated the active reporting volume of medical institutions, but the 200% floating space is still relatively uncertain for enterprises
.

Compared with Liaoning, Henan has greatly reduced the floating range and limited it to 20%, which undoubtedly gives more impetus to related pharmaceutical companies
.

Compared with Liaoning, Henan has greatly reduced the floating range and limited it to 20%, which undoubtedly gives more impetus to related pharmaceutical companies
.

In fact, the cross-regional procurement alliance is undoubtedly one of the priorities of the local medical insurance bureaus this year
.
In February of this year, Chen Jinfu, deputy director of the National Medical Insurance Bureau, clearly pointed out that more and more varieties of centralized procurement by the alliance are an inevitable trend and a mainstream trend
.

On April 15, the Henan Provincial Medical Insurance Bureau announced that 13 provinces, including Henan, Shanxi, Inner Mongolia, Hebei, Hunan, Guangxi, Hainan, Chongqing, Guizhou, Qinghai, and Ningxia Xinjiang Construction Corps, formed an inter-provincial alliance
.
After all, Henan has participated in 4 provincial alliances before and after, and there are many overlapping varieties of centralized collection among the alliances
.

After all, Henan has participated in 4 provincial alliances before and after, and there are many overlapping varieties of centralized collection among the alliances
.

In a recent internal meeting of the National Medical Insurance Administration, it was clarified that by the end of 2022, all provinces (including inter-provincial alliances) will have a cumulative target of not less than 100 drug varieties for centralized procurement
.
It is foreseeable that inter-provincial alliance purchases formed spontaneously by various regions are also blooming everywhere, accelerating the formation of a new consumables price system with larger purchase volumes and stronger bargaining chips
.

By the end of 2022, each province (including the inter-provincial alliance) will conduct its own centralized procurement of no less than 100 drug varieties.

The superposition of various centralized procurement alliances makes it not difficult for each province to achieve the goal of 100 varieties
.
In the future, the form of centralized procurement will be more solid, and the bidding will be more intense
.

Analysts pointed out that in the future, the rules for centralized drug procurement will be more transparent and the competition will be more intense , and Henan can extend the rules of limited reporting to the whole country through cross-regional alliances
.

In the future, the rules for centralized drug procurement will be more transparent and competition will be more intense

This makes Henan's new regulations on reporting volume more practical.
In addition to centralized procurement, there is room for non-centralized procurement varieties.
This is the idea at the beginning of the design of the centralized procurement system
.
In the context of the normalization of centralized procurement, Henan is ready to move, so are other cities still far away?

In addition to centralized procurement, there is a certain space for non-centralized procurement varieties.
This is the idea at the beginning of the design of the centralized procurement system.